Screener
TG Therapeutics TGTX Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 82.4%-4.6pp | 83.1%-4.4pp | 83.7%-4.6pp | 85.3%-3.0pp | 87%-5.8pp | |
| Operating margin | 17.1%-1.9pp | 21.3%+5.9pp | 20%+7.3pp | 19.3%— | 18.9%— | |
| Net margin | 55.2%+41.9pp | 66%+55.8pp | 72.6%+65.5pp | 84.1%— | 13.3%— | |
| Returns | ||||||
| Return on equity | 100.3%+73.6pp | 112.6%+92.9pp | 102.8%+90.5pp | 112%— | 26.6%— | |
| Return on invested capital | 21.4%-4.5pp | 23.9%+3.6pp | 22%+5.9pp | 19.8%— | 25.8%— | |
| Efficiency | ||||||
| Asset turnover | 0.7×-0.1× | 0.6×-0.1× | 0.8×0.0× | 0.7×+0.1× | 0.8×-0.3× | |
| Liquidity | ||||||
| Current ratio | 4.3×+0.4× | 5.8×+1.8× | 4.1×-2.1× | 3.8×-0.8× | 3.9×+0.3× | |
| Leverage | ||||||
| Debt-to-equity | 1.2×+0.3× | 1.3×+0.2× | 0.4×-0.7× | 0.4×-0.9× | 0.9×+0.3× | |
| Net debt / EBITDA | 2×+0.5× | 2.1×+0.1× | 1.4×-0.3× | 1.7×— | 1.5×— | |
| Per Share | ||||||
| Book value per share | $3.84+126% | $3.64+150% | $4.01+189% | $3.77+215% | $1.70+52.7% | |
| Valuation | ||||||
| Market capitalization | $7.64B+73.6% | $5.3B-14.3% | $4.73B+1.0% | $5.73B+58.3% | $5.92B+115% | |
| Price / earnings | 17.3×-55.5× | 11.5×-147× | 10.6×-190× | 12.8×— | 97.9×— | |
| Price / sales | 9.6×-0.1× | 7.6×-8.5× | 7.7×-6.6× | 10.8×-2.9× | 13×+5.1× | |
| Price / book | 12.6×-3.3× | 9.1×-17.0× | 7.3×-13.8× | 9.4×-9.4× | 21.4×+5.9× | |
| EV / EBITDA | 58×+5.3× | 37.5×-67.9× | 39.8×-73.6× | 57.5×— | 70.4×— |
FAQ
- What are TG Therapeutics's profit margins?
- TG Therapeutics (TGTX) runs a 82.4% gross margin and a 17.1% operating margin, with a 55.2% net margin.
- Where do TG Therapeutics's ratios come from?
- Every ratio is computed from TG Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
